Showing 3002 results
-
Clinical Trials /
-
Press release /Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval…
-
Story /Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.
-
Event / Oct 23, 2026At the European Society for Medical Oncology (ESMO) Congress 2026, we will present the latest data from our oncology portfolio, demonstrating our ongoing commitment to driving progress in cancer…
-
Clinical Trials /
-
Biography /
-
Story /Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.